27 related articles for article (PubMed ID: 34311659)
1. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
[TBL] [Abstract][Full Text] [Related]
2. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).
Bloudek LM; Stokes M; Buse DC; Wilcox TK; Lipton RB; Goadsby PJ; Varon SF; Blumenfeld AM; Katsarava Z; Pascual J; Lanteri-Minet M; Cortelli P; Martelletti P
J Headache Pain; 2012 Jul; 13(5):361-78. PubMed ID: 22644214
[TBL] [Abstract][Full Text] [Related]
3. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
Buse DC; Krasenbaum LJ; Seminerio MJ; Packnett ER; Carr K; Ortega M; Driessen MT
Pain Ther; 2024 Jun; 13(3):511-532. PubMed ID: 38472655
[TBL] [Abstract][Full Text] [Related]
4. The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries.
Doane MJ; Gupta S; Fang J; Laflamme AK; Vo P
Neurol Ther; 2020 Dec; 9(2):535-549. PubMed ID: 32542532
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and associated costs among patients with migraine in Finland: A retrospective register-based study.
Kosunen M; Rossi J; Niskanen S; Metsä R; Kainu V; Lahelma M; Isomeri O
PLoS One; 2024; 19(3):e0300816. PubMed ID: 38507402
[TBL] [Abstract][Full Text] [Related]
6. Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe.
Doane MJ; Gupta S; Vo P; Laflamme AK; Fang J
Pain Ther; 2019 Dec; 8(2):203-216. PubMed ID: 31350710
[TBL] [Abstract][Full Text] [Related]
7. Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain.
Pozo-Rosich P; Carmo M; Muñiz A; Armada B; Moya-Alarcón C; Pascual J
BMC Neurol; 2024 Apr; 24(1):107. PubMed ID: 38566063
[TBL] [Abstract][Full Text] [Related]
8. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
Headache; 2024 Jun; ():. PubMed ID: 38898657
[TBL] [Abstract][Full Text] [Related]
9. Costs and Health Care Utilization Analysis of Medical Group Visits for Adults With Type 2 Diabetes in Community Health Centers.
Wan W; Staab EM; Li J; GoodSmith M; Campbell A; Schaefer CT; Quinn MT; Huang ES; Baig AA
Med Care; 2023 Dec; 61(12):866-871. PubMed ID: 37819210
[TBL] [Abstract][Full Text] [Related]
10. Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study.
Jones S; Castell C; Goday A; Smith HT; Nicolay C; Simpson A; Salaun-Martin C
Clinicoecon Outcomes Res; 2012; 4():383-93. PubMed ID: 23277741
[TBL] [Abstract][Full Text] [Related]
11. Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey.
García-Azorín D; Moya-Alarcón C; Armada B; Sánchez Del Río M
J Headache Pain; 2024 Mar; 25(1):38. PubMed ID: 38486155
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review.
Barbanti P; Allais G; Cevoli S; Guerzoni S; Valeriani M; Vernieri F
Pain Ther; 2024 Jun; 13(3):319-346. PubMed ID: 38446344
[TBL] [Abstract][Full Text] [Related]
13. Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine.
Ambat FDF; Bentivegna E; Martelletti P
BioDrugs; 2022 May; 36(3):337-339. PubMed ID: 35575969
[TBL] [Abstract][Full Text] [Related]
14. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain.
Vo P; Swallow E; Wu E; Zichlin ML; Katcher N; Maier-Peuschel M; Naclerio M; Ritrovato D; Tiwari S; Joshi P; Ferraris M
J Med Econ; 2021; 24(1):900-907. PubMed ID: 34311659
[TBL] [Abstract][Full Text] [Related]
15. Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain.
Vo P; Gao W; Zichlin ML; Fuqua E; Fadli E; Aguirre Vazquez M; Tarancón T; Mahieu N; Maier-Peuschel M; Rossi S; Naclerio M; Ritrovato D; Swallow E
J Med Econ; 2019 Sep; 22(9):960-966. PubMed ID: 31234676
[No Abstract] [Full Text] [Related]
16. Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain.
Vo P; Gao W; Zichlin ML; Fuqua E; Fadli E; Aguirre Vazquez M; Tarancón T; Mahieu N; Maier-Peuschel M; Rossi S; Naclerio M; Ritrovato D; Swallow E
J Med Econ; 2019 Sep; 22(9):953-959. PubMed ID: 31234672
[No Abstract] [Full Text] [Related]
17. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study.
Kollewe K; Gaul C; Gendolla A; Sommer K
J Headache Pain; 2021 Jun; 22(1):50. PubMed ID: 34078259
[TBL] [Abstract][Full Text] [Related]
18. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
19. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
